Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of certain tyrosine kinase-driven tumors. It interferes with abnormal signaling pathways in cancer cells by selectively inhibiting specific kinases involved in cell proliferation and survival. This compound has shown activity against tumor cell lines with mutations in growth-regulating enzymes, making it valuable in research for personalized oncology treatments. It is primarily utilized in preclinical studies to evaluate efficacy, pharmacokinetics, and mechanism of action in solid tumors and hematologic malignancies. Its structure allows for enhanced binding affinity and selectivity, which may reduce off-target effects in therapeutic applications.